These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 32563812)

  • 1. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.
    Liang C; Tian L; Liu Y; Hui N; Qiao G; Li H; Shi Z; Tang Y; Zhang D; Xie X; Zhao X
    Eur J Med Chem; 2020 Sep; 201():112527. PubMed ID: 32563812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
    Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR
    Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid review for the anti-coronavirus effect of remdesivir.
    Li Z; Wang X; Cao D; Sun R; Li C; Li G
    Drug Discov Ther; 2020; 14(2):73-76. PubMed ID: 32378648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
    Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Pérez-Pérez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E
    Nature; 2020 Sep; 585(7824):273-276. PubMed ID: 32516797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of Remdesivir for COVID-19: Data to Date.
    Mehta M; Shyh GI
    Cardiol Rev; 2020; 28(6):332-334. PubMed ID: 32773440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
    Jorgensen SCJ; Kebriaei R; Dresser LD
    Pharmacotherapy; 2020 Jul; 40(7):659-671. PubMed ID: 32446287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process.
    Ison MG; Wolfe C; Boucher HW
    JAMA; 2020 Jun; 323(23):2365-2366. PubMed ID: 32407438
    [No Abstract]   [Full Text] [Related]  

  • 9. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2020; 14(4):641-648. PubMed ID: 32428865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncertainty about the Efficacy of Remdesivir on COVID-19.
    Yoo JH
    J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of remdesivir for patients with Covid-19: a review article.
    Azevedo TCP; Azevedo PCP; Silveira Filho RN; Carvalho ARVS; Cezarotti Filho ML; Barbosa FT; Sousa-Rodrigues CF; Matos-Rocha TJ; Ramos FWDS
    Rev Assoc Med Bras (1992); 2020 Jun; 66(6):838-841. PubMed ID: 32696862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
    Hashemian SM; Farhadi T; Velayati AA
    Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report study of the first five COVID-19 patients treated with remdesivir in France.
    Dubert M; Visseaux B; Isernia V; Bouadma L; Deconinck L; Patrier J; Wicky PH; Le Pluart D; Kramer L; Rioux C; Le Hingrat Q; Houhou-Fidouh N; Yazdanpanah Y; Ghosn J; Lescure FX
    Int J Infect Dis; 2020 Sep; 98():290-293. PubMed ID: 32619764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.
    Chua KP; Conti RM
    JAMA Intern Med; 2020 Oct; 180(10):1273-1274. PubMed ID: 32804187
    [No Abstract]   [Full Text] [Related]  

  • 15. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
    Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
    Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.
    Musa A; Pendi K; Hashemi A; Warbasse E; Kouyoumjian S; Yousif J; Blodget E; Stevens S; Aly B; Baron DA
    West J Emerg Med; 2020 May; 21(4):737-741. PubMed ID: 32726230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?
    Thalha AMM; Lee YY; Besari A; Omar SFS
    J R Coll Physicians Edinb; 2020 Jun; 50(2):159-161. PubMed ID: 32568289
    [No Abstract]   [Full Text] [Related]  

  • 18. Remdesivir: First Approval.
    Lamb YN
    Drugs; 2020 Sep; 80(13):1355-1363. PubMed ID: 32870481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.
    Cao YC; Deng QX; Dai SX
    Travel Med Infect Dis; 2020; 35():101647. PubMed ID: 32247927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.